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ABSTRACT
Circulating miRNAs (microRNAs) are emerging as promising biomarkers for several pathological
conditions, and the aim of this study was to investigate the feasibility of using serum miRNAs as
biomarkers for liver pathologies. Real-time qPCR (quantitative PCR)-based TaqMan MicroRNA
arrays were ﬁrst employed to proﬁle miRNAs in serum pools from patients with HCC
(hepatocellular carcinoma) or LC (liver cirrhosis) and from healthy controls. Five miRNAs (i.e.
miR-885-5p, miR-574-3p, miR-224, miR-215 and miR-146a) that were up-regulated in the HCC
and LC serum pools were selected and further quantiﬁed using real-time qPCR in patients with
HCC, LC, CHB (chronic hepatitis B) or GC (gastric cancer) and in normal controls. The present
study revealed that more than 110 miRNA species in the serum samples and wide distribution
ranges of serum miRNAs were observed. The levels of miR-885-5p were signiﬁcantly higher
in sera from patients with HCC, LC and CHB than in healthy controls or GC patients. miR-
885-5p yielded an AUC [the area under the ROC (receiver operating characteristic) curve]
of 0.904 [95% CI (conﬁdence interval), 0.837–0.951, P<0.0001) with 90.53% sensitivity and
79.17% speciﬁcity in discriminating liver pathologies from healthy controls, using a cut off value of
1.06 (normalized). No correlations between increased miR-885-5p and liver function parameters
[AFP (α-fetoprotein), ALT (alanine aminotransferase), AST (aspartate aminotransferase) and GGT
(γ-glutamyl transpeptidase)] were observed in patients with liver pathologies. In summary,
miR-885-5p is signiﬁcantly elevated in the sera of patients with liver pathologies, and our data
suggest that serum miRNAs could serve as novel complementary biomarkers for the detection
and assessment of liver pathologies.
INTRODUCTION
Liver diseases including CHB (chronic hepatitis B), LC
(liver cirrhosis) and HCC (hepatocellular carcinoma) are
public health concerns and major medical challenges
in the People’s Republic of China [1,2]. Clinically,
a panel of serological biochemical markers including
aminotransferase [ALT (alanine aminotransferase)/AST
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(aspartate aminotransferase)] and AFP (α-fetoprotein)
have been used to monitor liver pathologies for several
decades, but they have limited sensitivity and speciﬁcity
particularlywithregardtotheinsidiousprogressofHCC
[3,4].
miRNAs (microRNAs) are small non-coding RNAs
of 22–25 nucleotides that play important roles in
regulating gene expression by binding to and regulating
theactivityoftheirtargetmRNAspost-transcriptionally,
contributing to diverse cellular processes such as pro-
liferation, differentiation, apoptosis and carcinogenesis
[5]. Expression of miRNAs is consistently deregulated
in some physiopathological conditions including cancer
[6–9]. miRNAs in plasma/serum are emerging as a
new class of potential markers for minimally invasive
diagnosisandmonitoringofpatientswithseveraldiseases
[10–12]. Serum miR-21 has been reported to be elevated
in lymphoma patients [13], plasma miR-92a can be used
to identify patients with colorectal cancer [14] and miR-1
andmiR-208couldserveasindicatorsofacutemyocardial
infarction [15,16].
The regulatory roles of miRNAs in the development
of liver-related pathologies including HCC, CHB and
chronic hepatitis C have been elucidated [17–20],
andcirculatingmiRNAsincludingmiR-122andmiR-192
have been reported to have diagnostic value for toxin-
induced hepatocellular damage in mice [21]. However,
the potential clinical value of circulating miRNAs for
diagnosing and managing liver pathologies has not been
evaluated. The present study investigates the hypothesis
thatdifferentiallyexpressedmiRNAscirculateinpatients
with liver pathologies. We ﬁrst proﬁled serum miRNA
expression in patients with HCC and LC. Next, ﬁve
differently expressed miRNAs were selected and further
evaluated in independent patient cohorts. Our study
indicates that the various levels of speciﬁc miRNAs,
especially miR-885-5p, could serve as markers for the
preclinical detection and clinical assessment of patients
with such diseases.
MATERIALS AND METHODS
Study design
The present study was performed in three phases: (i)
global serum miRNA proﬁling using a TaqMan Human
MicroRNA Array, in combination with Megaplex
RT and Megaplex preampliﬁcation techniques; (ii) ana-
lysis and preliminary evaluation of candidate miRNAs;
and (iii) independent validation of selected miRNAs.
Each phase was conducted using independent groups of
participants.
Participants
To screen miRNAs more efﬁciently as potential markers
for liver-related diseases during the circulating miRNA
proﬁling phase, we ﬁrst generated seven pools of serum
aliquots derived from individuals in the case and control
groups. In brief, serum samples from 15 pathologically
conﬁrmed HCC patients with moderate histological
grade and various degrees of liver cirrhosis (light to
moderate) were randomly divided into three groups
to generate three serum pools, and serum samples
from ten patients clinically diagnosed as moderate to
decompensated LC were similarly used to generate two
pools. Each serum pool consisted of equal volumes of
serum from all patients within the group. In addition,
serum samples from ten age-matched healthy individuals
were obtained to generate two NC (normal control)
pools, so a total of seven serum pools were generated
for miRNA proﬁling.
To quantify individual miRNAs, independent sets of
serum samples were obtained between November 2008
and January 2010 from patients with liver pathologies
[CHB, LC, HCC, ICC (intrahepatic cholangiocellular
carcinoma) and FNH (focal nodular hyperplasia)] who
were admitted to or hospitalized in the Department
of Hepatobiliary Surgery or the Department of
Gastroenterology in the Chinese PLA General Hospital
(Beijing).
Collectively, none of the enrolled HCC, ICC and
FNH patients had received any adjuvant therapy
or other treatment before blood sampling, none of
the CHB and LC patients had received treatment
within 3 weeks before blood sampling and most of
the LC patients were diagnosed as HBV (hepatitis B
virus)-related liver cirrhosis. Additionally, age-matched
healthy individuals were recruited as NCs, and serum
samples from patients with newly diagnosed GC
(gastric cancer) were used as disease controls. The
baseline characteristics of the recruited subjects are
displayed in Supplementary Table S1 (available at
http://www.clinsci.org/cs/120/cs1200183add.htm) and
see Table 2.
Written informed consent was obtained from each
individual or their responsible guardians. This study
protocol was approved by the ethics committee of the
Chinese PLA General Hospital (Beijing).
Serum sample processing and RNA
isolation
Peripheral blood was collected in tubes containing
separating gel and clot activator and centrifuged at 3400 g
for 7 min at room temperature, and the supernatants
were transferred to Eppendorf tubes. The samples were
centrifuged at 15000 g for 8 min to precipitate cell debris,
and the supernatants were stored at −80◦C pending
RNA extraction. All blood samples were processed
within 24 h after they were obtained.
Total serum RNA was isolated and eluted in 100 μl
of RNase-free water using a mirVana PARIS kit (#1556;
Ambion) following the manufacturer’s protocol for
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liquid samples. For miRNA proﬁling, 800 μl of pooled
serum was used, and for individual miRNA tests,
400 μl of serum from each participant was used. All
serum RNA preparations were quantiﬁed using a DU
800 spectrophotometer (Beckman Coulter) and then
pretreated with RNase-free DNase I (Promega) to
eliminate potential DNA contamination.
Serum miRNA proﬁling and data analysis
In our study, a three-step procedure was performed to
proﬁle the miRNAs in the pooled serum samples. First,
for cDNA synthesis from the miRNAs, 10 ng of total
RNAfromthepooledserumwassubjectedtoRT(reverse
transcription) using a TaqMan® microRNA Reverse
Transcription Kit (#4366596; Applied Biosystems) and
Megaplex RT primers (Human Pool A, #4399966;
Applied Biosystems) following the manufacturer’s
protocol, allowing simultaneous reverse transcription of
380 mature human miRNAs to generate an miRNA
cDNAlibrarycorrespondingtoeachserumpool.RTwas
performed on a Mastercycler Epgradient thermocycler
(Eppendorf) with the following cycling conditions: 40
cycles of 16◦C for 2 min, 42◦C for 1 min and 50◦Cf o r
1 s,followedbyaﬁnalstepof80◦Cfor5 mintoinactivate
the reverse transcriptase.
Thereafter, to generate enough miRNA cDNA
template for the following real-time PCR, the cDNA
libraries were pre-ampliﬁed using Megaplex PreAmp
primer (Humam Pool A, #4399233; Applied Biosystems)
andPreAmpMasterMix(#4384266;AppliedBiosystems)
following the manufacturer’s instructions. The PreAmp
primer pool used here consisted of forward primers
speciﬁc for each of the 380 human miRNAs and a
universal reverse primer. The preampliﬁcation cycling
conditions were as follows: 95◦C for 10 min, 55◦Cf o r
2 min, 72◦C for 2 min followed by 12 cycles of 95◦C
for 30 s and 60◦C for 4 min; the samples were then held
at 99.9◦C for 10 min.
After the preampliﬁcation step, the products were
diluted with RNase-free water, combined with TaqMan
gene expression Master Mix and then loaded into
TaqMan Human MicroRNA Array A (#4398965;
Applied Biosystems), which is a 384-well formatted
plate and real-time PCR-based microﬂuidic card with
embedded TaqMan primers and probes in each well
for the 380 different mature human miRNAs; the
Mamm U6 (mammalian U6) transcript was used as
a normalization signal. qPCR (quantitative PCR) was
performed according to the manufacturer’s instructions.
Real-time PCR was performed on an ABI PRISM
7900HTsequencedetectionsystem(AppliedBiosystems)
with the following cycling conditions: 50◦C for 2 min,
94.5◦C for 10 min followed by 40 cycles of 95◦Cf o r
30 s and 59.7◦Cf o r1 m i n .T h eCt (cycle threshold)
was automatically given by SDS 2.3 software (Applied
Biosystems) and is deﬁned as the fractional cycle number
atwhichtheﬂuorescencepassestheﬁxedthresholdof0.2.
MammU6embeddedintheTaqManHumanMicroRNA
Arrays was used as an endogenous control.
The relative expression levels of miRNAs were
calculated using the comparative   Ct method as
described previously [22,23]. The fold changes in
miRNAs were calculated by the equation 2−  Ct.
Cluster 3.0 software was used to perform unsupervised
hierarchicalclusteringusingPearson’scorrelationmetrics
and average linkage methods. Java Treeview 1.1.3 was
used to visualize the clustering results.
Measurement of liver function parameters
The concentrations/activities of serum aminotransferases
(ALT and AST) and AFP in each serum sample were
measured using a Hitachi 7600 Modular Analytic system.
TaqMan miRNA assay for individual
miRNAs
Individual miRNA tests were performed on independent
setsofserumsamplesandatwo-stepprocedurewasused.
First, 5 ng of total RNA isolated from 400 μl of each
serum sample was subjected to RT using an miRNA-
speciﬁc primer from the TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems) as described
previously [10]. Brieﬂy, RT was conducted in a scaled-
down RT reaction volume of 7.5 μl, which contained
2.08 μl of water, 0.75 μlo f1 0 × RT buffer, 0.095 μlo f
RNase inhibitor, 0.075 μl of dNTPs with dTTP, 0.5 μl
of multiscribe reverse transcriptase, 1.5 μl of miRNA-
speciﬁc stem-loop RT primer (Applied Biosystems) and
2.5 μl (5 ng) of digested RNA preparations. RT was
carried out on a Mastercycler Epgradient at 16◦Cf o r
30 min, 42◦C for 30 min and 85◦C for 5 min.
Thereafter, real-time qPCR was performed using
a TaqMan MicroRNA assay (Applied Biosystems) to
quantifyindividualmiRNAsasdescribedpreviously[10].
In brief, 4.5 μl of 5:28 diluted RT product was combined
with 5.0 μl of TaqMan gene expression Master Mix
and 0.5 μl of Taqman miRNA assay mix. qPCR was
carried out on an ABI PRISM 7300 sequence detection
system at 95◦C for 5 min, followed by 40 cycles of 95◦C
for 15 s and 60◦C for 1 min. All qPCR reactions were
performed in triplicate and the Ct values greater than
35 from the real-time PCR assays were treated as 35.
The PCR products were analysed by electrophoresis on
3.0% agarose gels to validate the speciﬁc generation of
the expected product. The expression levels (2−  Ct)
of miRNAs were calculated as described previously [22].
Statistical analysis
The Mann–Whitney test or Kruskal–Wallis test was
performedtodeterminethesigniﬁcanceofserummiRNA
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levels. MedCalc 9.6.4 software was used to construct
ROC (receiver operating characteristic) curves and
calculate the AUC (area under the ROC curve). Linear
regression analysis was used to examine correlations
between the levels of the miRNAs and liver function
parameters. P values <0.05 were considered statistically
signiﬁcant. All statistical calculations were performed
using SPSS software (version 11.0).
RESULTS
Serum miRNA proﬁling and data analysis
The ﬁrst aim of the present study was to investigate
whether aberrantly expressed miRNAs are present in
patients with liver pathologies. To screen differentially
expressed miRNAs in serum samples efﬁciently, we
generated seven serum pools of serum aliquots
derived from individuals in the NC, LC and HCC
groups (two NC, two LC and three HCC pools).
The circulating miRNAs in the seven serum pools
were proﬁled separately using RT-preamp-qPCR (RT-
preampliﬁcation-qPCR)asdescribedintheMaterialsand
methods section.
The data indicated that a total of 115 miRNAs could
be detected (assays giving Ct values <33 in at least four
pools were classed as detectable) (results not shown). By
comparing the miRNA proﬁles between HCC and NC
and LC and NC, two miRNA expression patterns were
obtained (Table 1). This process generated a list of more
than 20 up-regulated candidate miRNAs. As shown in
Table 1, the average levels of 26 miRNAs in the HCC
serumpoolsand22miRNAsintheLCserumpools were
higher than in NC.
To investigate the relative abundances of the miRNAs
detected, they were normalized in each serum pool (NC,
LC and HCC) to Mamm U6 in the corresponding pool.
AsshowninFigure1,miRNAssuchasmiR-223,miR-16
and miR-146a were present in relatively high abundance
intheserumsamples,whilemiR-99a,miR-224,miR-192,
miR-128andmiR-100werepresentatsigniﬁcantlylower
abundance compared with the corresponding Mamm
U6 (28.1 in NC, 29.4 in LC and 30.0 in HCC pool,
respectively). In addition, the abundances of different
miRNA species in a speciﬁed serum pool varied widely.
For example, the relative abundances (normalized to
Mamm U6)o fmiR-223 and miR-100 in the NC serum
pool were 295.09 and 0.00026, respectively.
Furthermore, unsupervised hierarchical clustering
analysis demonstrated that different serum pools had
different miRNA spectra (Figure 2A), and a small panel
of miRNAs including miR-146a, miR-224, miR-574-3p
and miR-885-5p were clustered together because of their
similarly up-regulated expression in HCC serum pools
compared with NC serum pools (Figure 2B).
Table 1 Up-regulated miRNAs in serum pools of HCC and
LC
Fold change was calculated as described previously [14] and is presented as
2−  Ct. miRNAs with mean fold change >2 in HCC serum pools (n=3) and
>1.5 in LC serum pools (n=2) when compared with NC (n=2) are listed
respectively. miRNAs underlined are common miRNAs with up-regulated levels in
both HCC and LC when compared with NC. The ﬁve miRNAs highlighted in bold
represent HCC/LC-related candidate miRNAs selected for subsequent validation.
miRNAs in serum of miRNAs in serum of
HCC compared with NC LC compared with NC
Average fold Average fold
miRNA change miRNA change
miR-99a 191.3 miR-99a 328.4
miR-224 87.1 miR-100 59.5
miR-100 82.5 miR-125b 29.7
miR-122 16.3 miR-128 14.7
miR-885-5p 13.5 miR-215 14.4
miR-125b 8.5 miR-224 14.1
miR-95 7.9 miR-192 8.9
miR-215 7.8 miR-194 8.2
miR-134 7.3 miR-133a 7.7
miR-194 6.3 miR-210 7.0
miR-192 5.7 miR-375 6.6
miR-193b 5.7 miR-423-5p 5.7
let-7b 5.2 miR-185 5.3
miR-133a 5.1 miR-141 5.2
miR-483–5p 5.0 miR-122 5.2
miR-886–3p 4.7 miR-19b 4.3
miR-574-3p 4.6 miR-885-5p 2.7
let-7d 3.7 miR-16 2.7
miR-146a 3.4 miR-574-3p 1.9
miR-18a 3.1 miR-30b 1.8
miR-141 2.9 miR-146a 1.6
miR-486-5p 2.8 miR-26a 1.5
miR-222 2.7
miR-181a 2.5
miR-92a 2.2
miR-16 2.0
Candidate miRNAs selection and
preliminary evaluation
In this phase, preliminary tests of candidate miRNAs
were carried out on a second set of serum samples
including NC (n=16) and patients with LC (n=12) or
HCC (n=20) (Supplementary Table S1).
Initially, the expression of U6 snRNA (small nuclear
RNA) and miR-16 (both proposed as the most
commonly used internal controls in the literature
[14,24–26]) in sera from NC, LC and HCC was
determined using real-time qPCR in order to select
suitable internal controls. Both U6 snRNA and miR-
16 were speciﬁcally and consistently detected in all
sera (Supplementary Figures 1A and 1B available at
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Table 2 Clinical characteristics of participants in validation
Ages are given as means (S.D.), and AFP, ALT, AST and TB are given as medians (range). No-HCC, patients with liver diseases including nine with ICC and six with
FNH. In the LC group, 18 patients had decompensated liver function. HBsAg, hepatitis B surface antigen; ND, not detected; TB, total bilirubin.
Group HCC Non-HCC LC CHB GC NC
Individuals (n) 4 61 52 62 31 7 2 4
Gender (n)
Male 39 12 23 17 15 17
F e m a l e 73362 7
Age (years) 54.2 (9.2) 45.7 (8.6) 61.2 (10.2) 41.3 (8.9) 58 (7.5) 50.6 (5.6)
AFP (ng/ml) 38.8 (1.62–20000) 2.97 (1.1–422.3) 4.22 (0.61–365.9) 3.6 (1.22–23.7) 1.81 (1.02–6.87) 2.6 (1.23–6.38)
Abnormal (AFP >20 ng/ml) (n) 2 43320 0
Normal (AFP<20 ng/ml) (n) 2 21 21 91 11 2 2 4
ND (n) 0 04 1 050
ALT (units/l) 34.1 (17.8–421.9) 29.8 (9.1–281.8) 28.9 (14.5–101.9) 27.4 (5.8–137.2) 13.8 (7.6–50.1) 17.2 (13.1–32.6)
AST (units/l) 31.1 (9.1–281.8) 26.3 (9.4–540.5) 33.7 (14.7–85.1) 25.1 (10.2–296) 15.8 (10.6–24.1) 15.1 (8.2–29.6)
GGT (units/l) 61.2 (11.5–908.0) 62.3 (15.7–1310) 59.3 (24.8–199.3) 26.1 (12.3–118.5) 18.6 (7.6–135.2) ND
TB (μmol/l) 14.2 (6.0–227.3) 11.4 (5.4–377.2) 19.6 (7.5–47.7) 10.3 (2.8–32.8) 9.6 (2.3–56.9) ND
HbsAg (n)
P o s i t i v e 3 322 02 300
Negative 13 12 5 0 16 24
Not known 0 1 1 0 1 0
Cirrhosis (n)
Normal 0 13 0 Unknown – –
Low 17 2 0 Unknown – –
Moderate 29 0 12 Unknown – –
High 0 0 14 Unknown – –
Histological grade (n)
Good 6 – – – – –
Moderate 32 – – – – –
Poor 8 – – – – –
Figure 1 Expression of 115 miRNAs in representative serum
pools from the NC, LC and HCC groups
miRNAs were quantiﬁed using RT-preamp-qPCR as described in the Materials and
methods section. The relative abundance of each miRNA is presented as 2− Ct,
where  Ct was calculated by subtracting the Ct values of Mamm U6 (28.1 in
NC, 29.4 in LC and 30.0 in HCC pool, respectively) from the Cto fe a c hm i R N A
detected within the corresponding groups. The levels of various miRNAs are shown
(normalized) in representative NC, LC and HCC serum pools.
http://www.clinsci.org/cs/120/cs1200183add.htm), with
an average raw Ct of 32.8 for U6 snRNA and 24.7
for miR-16. No signiﬁcant differences in raw Ct values
of U6 snRNA were detected among the three groups
(P= 0.128,Kruskal–Wallistest),buttherewasvariability
among the raw Ct values within the respective groups.
miR-16 was signiﬁcantly higher in HCC sera than in NC
and LC (P= 0.014, Kruskal–Wallis test). Therefore U6
snRNAwasselectedastheinternalnormalizationcontrol
for the subsequent miRNA qPCR.
Additionally, miRNAs such as miR-99a, miR-100 and
miR-125b were excluded from further analysis because
their expression levels were signiﬁcantly lower than
Mamm U6 in global miRNA proﬁling (Figure 1). As
a pilot study, the potentially increased expressions of a
subset of miRNAs (i.e. miR-146a, miR-215, miR-224,
miR-574-3p and miR-885-5p) were assessed using a
TaqMan microRNA assay (Figure 2 and Table 1).
Both miR-885-5p and miR-146a were consistently and
speciﬁcally detected in all 48 serum samples (i.e. all
with average Ct values <35) (Supplementary Figure 1C).
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Figure 2 Serum miRNAs proﬁled using real-time qPCR-based arrays
(A) miRNA expression proﬁles in two NC, two LC and three HCC serum pools. Assays with Ct values <33 in at least four pools were classed as detectable, and a total
of 115 miRNAs were detected. The expression levels of miRNAs were normalized to Mamm U6 and data are presented as 2− Ct. miRNA expression was mean-centred,
and a heat map was generated using Pearson’s correlation metrics and average linkage methods of Cluster 3.0 software. Samples are shown in columns and miRNAs
in rows. (B) miR-146a, miR-128, miR-224, miR-574-3p, miR-134 and miR-885-5p were clustered together. The colour of each cell represents the expression level of
the corresponding miRNA in the corresponding sample. The higher intensities of yellow relate to higher expression levels, and the increasing intensities of blue reﬂect
lower expression of miRNAs.
However, regarding mean Ct <35 as a positive signal, the
detection rates for miR-574-3p and miR-224 were 71%
and 23%, respectively.
Using U6 snRNA as the normalization control, we
demonstrated that miR-885-5p was signiﬁcantly higher
in HCC and LC serum samples than in NC (P<0.0001),
with a 6.5-fold increase in HCC and an 8.8-fold in LC
(Figure 3A). In addition, increased amounts of serum
miR-146a and miR-224 were observed in the HCC and
LC groups (Figures 3B and 3C). However, no signiﬁcant
differences in the levels of miR-574-3p were observed
among the NC, LC and HCC groups (Figure 3D), and
the low level of miR-215 made it difﬁcult to quantify its
abundance in the sera accurately using real-time qPCR
(most mean Ct values >35).
Validation of miR-885-5p as a potential
liver pathology-associated marker
ConsideringthatthelevelofmiR-885-5pwasconsistently
increased in serum samples from the HCC and LC
groups (Figure 3A), the abundance of this miRNA
was further measured in another independent cohort
of serum samples consisting of LC (n=26), HCC
(n=46), CHB (n=23), ICC (n=9), FNH (n=6) and
NC (n=24). In addition, 17 patients with GC were
included as disease controls to investigate the speciﬁcity
of miR-885-5p as a liver pathology-associated molecule.
Information regarding the disease control individuals in
terms of demographics, biochemical testing, virological
investigation and histological grade is summarized in
Table 2.
The data demonstrated that patients with HCC,
LC or CHB had signiﬁcantly (P<0.0001) higher
serum levels of miR-885-5p than normal controls and
GC patients (Figure 4A and Supplementary Table
S2 at http://www.clinsci.org/cs/120/cs1200183add.htm).
There was no statistically signiﬁcant difference in the
serum levels of miR-885-5p between normal controls
and patients with GC (P= 0.19, Mann–Whitney test).
Furthermore, ROC analysis indicated that using a cut
off value of 1.06 (2− Ct in comparison with U6 snRNA),
miR-885-5p yielded an AUC of 0.904 (95% CI: 0.837–
0.951, P<0.0001) that could be used to discriminate
patientswithliverpathologies(LC,n=26;HCC,n=46;
and CHB, n=23) from normal controls (n=24), with
speciﬁcity andsensitivityof 90.5 and 79.2%,respectively
(Figure4B).Forcomparison,ALTwasusedtodistinguish
patients from healthy controls and yielded an AUC of
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Figure 3 Comparisons of levels of serum miRNAs in NC, HCC and LC groups
Serum abundances of miR-885-5p (A), miR-146a (B), miR-224 (C) and miR-574-3p (D) in an independent set of serum samples from NC (n=16), HCC (n=20) and
LC (n=12) were quantiﬁed using real-time qPCR. Each qPCR was carried out in triplicate in 96-well plates. Expression levels of selected miRNAs were normalized to
U6 snRNA and are presented as fold changes (2−  Ct) above NC. Data are shown as the mean fold changes compared with the mean value in NC (+ −S.E.M.). A
Mann–Whitney or Kruskal–Wallis test was used to determine statistical signiﬁcance. ***P <0.0001, **P <0.001, *P <0.01.
0.742 (Figure 4C). In addition, miR-885-5p levels in the
sera of patients with ICC and FNH were also increased
(Figure 4D).
Relationships between serum miR-885-5p
and liver pathology parameters
To examine whether elevated serum miR-885-5p was
correlated with traditional liver disease markers such
as ALT and AST, linear regression analysis was
used to investigate the relationships between miR-
885-5p and AFP, ALT, AST and GGT in patients
with liver pathologies. There was no correlation
between serum miR-885-5p and ALT in 95 patients
with liver pathologies (LC, n=26, HCC, n=46,
CHB, n=23) (Supplementary Figure 2A available at
http://www.clinsci.org/cs/120/cs1200183add.htm). Sim-
ilar results were obtained for miR-885-5p compared with
AST and miR-885-5p compared with GGT (results not
shown). There was an increase in AFP concentrations in
46 patients with pathologically conﬁrmed HCC (closed
circles),butthelevelsofserummiR-885-5p(opencircles)
did not increase (Supplementary Figure 2B).
Multiple factors including age, gender, miR-885-5p,
AFP, ALT, AST and GGT in patients with liver
pathologies were used to establish a logistic regression
model. This model revealed that miR-885-5p was a
potential marker for the detection of liver pathologies
(P<0.0001), and the odds ratio for an individual with
miR-885-5p>1.12beingassociatedwithliverpathologies
was 16.3 (95% CI: 6.43–25.37).
DISCUSSION
Recent ﬁndings have exposed circulating miRNAs as
potential biomarkers for several disease conditions
including human cancer [10–16,20–21,24–27]. To our
knowledge, this report is the ﬁrst to investigate the
feasibility of using serum miRNAs as indicators of liver
pathologies. We found that individuals with HCC, LC
and CHB had signiﬁcantly elevated levels of serum miR-
885-5p. miR-885-5p yielded an AUC of 0.904 (95%
CI: 0.837–0.951, P<0.0001) with 90.53% sensitivity and
79.17% speciﬁcity in terms of discriminating patients
with liver pathologies from healthy controls and, more
importantly, had a better diagnostic performance than
ALT (74.2%). The odds ratio for individuals with miR-
885-5p>1.012havingliverpathologieswas16.3(95%CI:
6.43–25.37). However, there was no correlation between
circulating miR-885-5p and AFP, ALT, AST and GGT,
and the level of serum miR-885-5p did not increase
despite an increase of AFP in the HCC group. There was
no signiﬁcant difference in serum levels of miR-885-5p
between normal controls and patients with GC. These
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Figure 4 Validation of miR-885-5p in an independent set of serum samples
(A) Box plots of serum levels (2− Ct)o fmiR-885-5p in NC (n=24), HCC (n=46), LC (n=26), CHB (n=23) and GC (n=17). Expression levels of miRNAs
were normalized to U6 snRNA (Log10 scale on y-axis). The upper and lower borders of the boxes indicate the 75th and 25th percentiles, respectively. The whisker
caps indicate the 90th and 10th percentiles. The horizontal lines in the boxes indicate the median values. Outliers are illustrated as circles. A Mann–Whitney or
Kruskal–Wallis test was used to determine statistical signiﬁcance. (B) ROC curve analysis of serum miR-885-5p to differentiate patients with liver pathologies (n=95)
from NC (n=24). miR-885-5p yielded an AUC of 0.904 with 93.8% sensitivity and 75.0% speciﬁcity in discriminating liver pathologies. (C) ROC curve analysis
indicated that ALT yielded an AUC of 0.742 in distinguishing patients with liver pathologies (n=95) from NC. (D) Scatter plots indicate that the expression of
miR-885-5p in serum samples from patients with ICC and FNH is greater than in controls (Log10 scale on y-axis). The horizontal lines across the data points indicate
the median values.
results suggest that serum miR-885-5p could potentially
be an independent and complementary liver pathology-
associated biomarker.
Clinically, new biomarkers are necessary to improve
the diagnosis and management of patients with liver
pathologies, particularly insidious liver impairment and
early HCC [1–2,28]. Recent advances in genomics
and proteomics have accelerated the discovery of many
potential markers for clinical use. The present study
comprises a preliminary investigation of the expression
of circulating miRNAs in clinical serum samples of
patients with liver pathologies. Using RT-preamp-qPCR
[12,29,30], more than 110 miRNA species were detected
in clinical samples. In agreement with the ﬁndings of
Mitchell et al. [10], miRNAs such as miR-223 and miR-
16 were present in the circulation with relatively high
abundance (Figure 1). In addition, a wide dynamic range
of distribution of serum miRNA species was observed;
for example, the relative abundances of miR-223 and
miR-100 were 295.09 and 0.00026 in the NC serum
pool, respectively (Figure 1), which may reﬂect the
differentoriginsandmetaboliccharacteristicsofdifferent
circulating miRNA species in vivo. Furthermore,
miRNAs in the pooled serum samples from patients
with HCC and LC were differentially expressed. As
shown in Figure 1, which shows the relative abundance
of each miRNA in three representative serum pools,
similar trends were observed when the miRNAs were
ranged according to their relative abundances, e.g. with
consistently relatively high copy numbers of miR-16
and relatively low abundance of miR-100 in each pool.
Additionally, some miRNAs showed up-regulated levels
in both the HCC and LC (Table 1) serum pools,
which may reﬂect the fact that, in most cases, HCC
develops in association with liver cirrhosis. Furthermore,
unsupervisedhierarchicalclusteringanalysisrevealedthat
different serum pools had different miRNA spectra
(Figure 2A), which besides some possible technical
variations in miRNAs proﬁling (discussed below) might
indicate that the circulating miRNAs in serum pools
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derived from different patients reveal different metabolic
characteristics. Additionally, Figure 2(B) shows that
miR-146a, miR-224, miR-574-3p and miR-885-5p were
clustered together because of their similarly up-regulated
expression in the HCC serum pools (Figure 2B).
As a pilot study, ﬁve miRNAs, miR-885-5p,
miR-574-3p, miR-224, miR-215 and miR-146a, that
are up-regulated in the HCC and LC serum pools
(Table 1) were selected and further quantiﬁed using real-
time PCR in independent sets of patients with HCC,
LC, CHB, ICC and FNH. Our case control study
conﬁrmed that serum miR-885-5p is consistently and
signiﬁcantly up-regulated in individuals with HCC, LC
and CHB (Figure 4A). The median values of miR-885-
5p in limited ICC and FNH cases were also elevated
(Figure 4D). Nevertheless, although four other miRNAs
(miR-574-3p, miR-224, miR-215 and miR-146a)w e r e
increased in the global miRNAs proﬁling experiment
(Table 1), we failed to validate their elevation in the
second groups of HCC and LC patients (Figures 3B–
3D). A probable reason for the discrepancies is that
although the TaqMan microRNA array is promising
for simultaneously measuring miRNAs expression in a
high-throughput manner [31,32], and the introduction
of an miRNA cDNA preampliﬁcation step signiﬁcantly
reduces the amount of RNA needed [30], potential
preampliﬁcation bias [30] may be responsible for some
variation in the Ct values and may thus diminish
the reproducibility with which miRNAs of low
abundance such as miR-574-3p, miR-224 and miR-215
can be quantiﬁed in the serum.
Recently, advances in circulating miRNAs research
[10–16] have generated the concept that tissue or
organ-speciﬁc intracellular miRNAs may be released
and/or leaked into the circulation during processes
accompanying cell death and/or apoptosis owing to cell
turnover, cellular destruction or pathological injury. It
has been suggested that comprehensive investigations
aimed at elucidating the associations between circulating
miRNAsandvariousphysiopathologicalconditionsmay
providenewopportunitiestouseplasma/serummiRNAs
as indicators in a clinical setting [10,11]. In view of their
relatively low complexity and excellent stability and the
availability of high throughput approaches such as ‘deep
sequencing’, it is possible to use a panel of circulating
miRNAs as markers to complement and/or improve
disease monitoring and management [10,33].
Furthermore, our ‘proof-of-principle’ observation
supports the idea that ‘normal’ compositions and levels
of circulating miRNAs can be deregulated under certain
disease conditions, and the ﬁnding that miR-885-5p is
up-regulated in the sera of patients with liver pathologies
could reﬂect a metabolic imbalance of this miRNA
in vivo. Additionally, other miRNAs such as miR-122
and miR-192 were elevated in patients with both
HCC and LC (Table 1). Interestingly, miR-122,a
liver-associated miRNA, was recently shown to be
increased signiﬁcantly in the circulation of toxicant-
treated mice [21]. Therefore the fact that miR-122 is
elevated in the sera of patients with liver pathologies
merits further investigation. However, it should be noted
that the conclusion that serum miR-885-5p is a potential
marker for liver pathologies is based on results from
a relatively small sample, and we could not analyse
the relationship between the elevated levels of serum
miR-885-5p and the severity and aetiology of liver
pathology. Therefore it might be interesting to enlarge
this study by prospective follow-up and investigate
the possible correlation between aberrant circulating
miR-885-5p and the progression of hepatic cir-
rhosis/ﬁbrosis. In addition, given that the metabolism
and function of circulating miRNAs remain unknown,
it is unclear whether serum miR-885-5p is liver-
restricted/derived or originates from immune cells
involved in the antiviral responses that accompany the
developmentofliverdiseases.Inanewlypublishedpaper
[34], miR-885-5p was found to be a relatively liver tissue-
enriched miRNA (Supplementary Figure S3 available at
http://www.clinsci.org/cs/120/cs1200183add.htm) and
our bioinformatics analysis indicates that ABCA1 (ATP-
bindingcassettesubfamilyAmember1),whichfunctions
as the gatekeeper of CRT (cholesterol reverse transport)
and is a key modulator in phosphatide metabolism,
is a potential target of miR-885-5p (Supplementary
Figure S4 and Supplementary Table S3 available at
http://www.clinsci.org/cs/120/cs1200183add.htm). That
mightmeanthatthismiRNAhassomeimportantcellular
function in the liver. Further investigation into the
expression of miR-885-5p in a variety of clinical liver
biopsies and related cell lines might help to elucidate
its biological role in the progression of chronic liver
diseases. Additionally, although our present observation
that the circulating miR-885-5p is signiﬁcantly up-
r e g u l a t e di np a t i e n t sw i t hH C C ,L Ca n dC H B ,f u t u r e
studies should include stratiﬁcation analysis of a large
sample to eliminate sample selection biases and to
clarify the pathological role of circulating miR-885-5p
at different stages of HCC and its correlation with
the degree of hepatic chronic inﬂammation and
the severity of liver impairment. Furthermore, as
mentioned earlier, since no correlation was found
between circulating miR-885-5p and traditional liver
parameters such as ALT, it will be interesting to in-
vestigate whether overexpressed circulating miR-885-5p
correlates with other liver function parameters and
hepatic histopathological indicators such as platelets,
serum albumin and Scheuer grading system in patients
with liver pathologies.
In summary, miR-885-5p was signiﬁcantly elevated
in sera from individuals with liver pathologies. The
detection method was sensitive and could be utilized
for minimally invasive and complementary detection of
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liverpathologiesinaclinicalsetting.Althoughtheclinical
signiﬁcance of these ﬁndings needs further investigation,
miRNAs could serve as novel screening and diagnostic
tools for detecting individuals with liver pathologies in
routine clinical practice.
AUTHOR CONTRIBUTION
Junhao Gui, Yaping Tian and Xinyu Wen designed the
study. Junhao Gui, Wenhui Zhang, Pengjun Zhang, Wei
Run and Liyuan Tian recruited the patients and provided
the samples. Jing Gao and Xingwang Jia determined
the liver function parameters, which was supervised by
Yanhong Gao. Junhao Gui and Wenhui Zhang collected
and assembled the data. Junhao Gui, Wenhui Zhang and
Yaping Tian performed data analysis and interpretation;
and Junhao Gui and Yaping Tian wrote the manuscript.
ACKNOWLEDGEMENTS
We thank Yueping Hua (Orbital Instruments, Beijing,
People’s Republic of China) and Yuantao Zhang (AB,
Beijing, People’s Republic of China) for their technical
support and suggestions. We acknowledge stimulating
discussions with Y.M. Lo, Joseph J.Y. Sung and
Hongchuan Jin (Prince of Wales Hospital, Hong Kong)
and Muneesh Tewari (Fred Hutchinson Cancer Research
Centre, Seattle, WA, U.S.A.) concerning the strategy for
quantifying circulating miRNAs.
FUNDING
This work was supported by the National Project
of Scientiﬁc and Technical Supporting Program [grant
number 2009BAI86B05] and National Science and
Technology Infrastructure Program [grant number
2006FY230300] funded by the Ministry of Science and
Technology of China.
REFERENCES
1 Fang, Y., Shang, Q. L., Liu, J. Y., Li, D., Xu, W. Z.,
Teng, X., Zhao, H. W., Fu, L. J., Zhang, F. M. and Gu,
H. X. (2009) Prevalence of occult hepatitis B virus
infection among hepatopathy patients and healthy people
in China. J. Infect. 58, 383–388
2 Zhou, H., Wang, H., Zhou, D., Wang, Q., Zou, S., Tu, Q.,
Wu, M. and Hu, H. (2010) Hepatitis B virus-associated
intrahepatic cholangiocarcinoma and hepatocellular
carcinoma may hold common disease process for
carcinogenesis. Eur. J. Cancer 46, 1056–1061
3 Aravalli, R. N., Steer, C. J. and Cressman, E. N. (2008)
Molecular mechanisms of hepatocellular carcinoma.
Hepatology 48, 2047–2063
4 Thorgeirsson, S. S., Lee, J. S. and Grisham, J. W. (2006)
Functional genomics of hepatocellular carcinoma.
Hepatology 43, S145–S150
5 Bartel, D. P. (2009) MicroRNAs: target recognition and
regulatory functions. Cell 136, 215–233
6 Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb,
J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H.,
Ferrando, A. A. et al. (2005) MicroRNA expression
proﬁles classify human cancers. Nature 435, 834–838
7 Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A.,
Bowman, E. D., Yanaihara, N., Yuen, S. T., Chan, T. L.,
Kwong, D. L. et al. (2008) MicroRNA expression proﬁles
associated with prognosis and therapeutic outcome in
colon adenocarcinoma. JAMA. J. Am. Med. Assoc. 299,
425–436
8 Anglicheau, D., Sharma, V. K., Ding, R., Hummel, A.,
Snopkowski, C., Dadhania, D., Seshan, S. V. and
Suthanthiran, M. (2009) MicroRNA expression proﬁles
predictive of human renal allograft status. Proc. Natl.
Acad. Sci. U.S.A. 106, 5330–5335
9 Li, S., Chen, X., Zhang, H., Liang, X., Xiang, Y., Yu, C.,
Zen, K., Li, Y. and Zhang, C. Y. (2009) Differential
expression of microRNAs in mouse liver under aberrant
energy metabolic status. J. Lipid Res. 50, 1756–1765
10 Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R.,
Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A.,
Noteboom, J., O’Briant, K. C., Allen, A. et al. (2008)
Circulating microRNAs as stable blood-based markers for
cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105,
10513–10518
11 Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J.,
Zhang, Y., Chen, J., Guo, X. et al. (2008) Characterization
of microRNAs in serum: a novel class of biomarkers for
diagnosis of cancer and other diseases. Cell Res. 18,
997–1006
12 Resnick, K. E., Alder, H., Hagan, J. P., Richardson, D. L.,
Croce, C. M. and Cohn, D. E. (2009) The detection of
differentially expressed microRNAs from the serum of
ovarian cancer patients using a novel real-time PCR
platform. Gynecol. Oncol. 112, 55–59
13 Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B.,
Liggins, A. P., Pulford, K., Banham, A. H., Pezzella, F.,
Boultwood, J., Wainscoat, J. S. et al. (2008) Detection of
elevated levels of tumour-associated microRNAs in serum
of patients with diffuse large B-cell lymphoma. Br. J.
Haematol. 141, 672–675
14 Ng, E. K., Chong, W. W., Jin, H., Lam, E. K., Shin, V. Y.,
Yu, J., Poon, T. C., Ng, S. S. and Sung, J. J. (2009)
Differential expression of microRNAs in plasma of
patients with colorectal cancer: a potential marker for
colorectal cancer screening. Gut 58, 1375–1381
15 Cheng, Y., Tan, N., Yang, J., Liu, X., Cao, X., He, P.,
Dong, X., Qin, S. and Zhang, C. (2010) A translational
study of circulating cell-free microRNAs-1 in acute
myocardial infarction. Clin. Sci. 119, 87–95
16 Ji, X., Takahashi, R., Hiura, Y., Hirokawa, G., Fukushima,
Y. and Iwai, N. (2009) Plasma miR-208 as a biomarker of
myocardial injury. Clin. Chem. 55, 1944–1949
17 Li, W., Xie, L., He, X., Li, J., Tu, K., Wei, L., Wu, J.,
Guo, Y., Ma, X., Zhang, P. et al. (2008) Diagnostic and
prognostic implications of microRNAs in human
hepatocellular carcinoma. Int. J. Cancer 123, 1616–1622
18 Ladeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P.,
Pelletier, L., Rebouissou, S. and Zucman-Rossi, J. (2008)
MicroRNA proﬁling in hepatocellular tumors is associated
with clinical features and oncogene/tumor suppressor gene
mutations. Hepatology 47, 1955–1963
19 Connolly, E., Melegari, M., Landgraf, P., Tchaikovskaya,
T., Tennant, B. C., Slagle, B. L., Rogler, L. E., Zavolan, M.,
Tuschl, T. and Rogler, C. E. (2008) Elevated expression of
the miR-17–92 polycistron and miR-21 in
hepadnavirus-associated hepatocellular carcinoma
contributes to the malignant phenotype. Am. J. Pathol.
173, 856–864
C   The Authors Journal compilation C   2011 Biochemical SocietyCirculating miR-885-5p and liver pathologies detection 193
20 Murakami, Y., Yasuda, T., Saigo, K., Urashima, T.,
Toyoda, H., Okanoue, T. and Shimotohno, K. (2006)
Comprehensive analysis of microRNA expression patterns
in hepatocellular carcinoma and non-tumorous tissues.
Oncogene 25, 2537–2545
21 Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman,
A., Hu, Z., Hood, L. E. and Galas, D. J. (2009) Circulating
microRNAs, potential biomarkers for drug-induced liver
injury. Proc. Natl. Acad. Sci. U.S.A. 106, 4402–4407
22 Schmittgen, T. D. and Livak, K. J. (2008) Analyzing
real-time PCR data by the comparative CT method. Nat.
Protoc. 3, 1101–1108
23 Livak, K. J. and Schmittgen, T. D. (2001) Analysis of
relative gene expression data using real-time quantitative
PCR and the 2−  CT method. Methods 25, 402–408
24 Zhu, W., Qin, W., Atasoy, U. and Sauter, E. R. (2009)
Circulating microRNAs in breast cancer and healthy
subjects. BMC Res. Notes 2,8 9
25 Wang, J., Chen, J., Chang, P., LeBlanc, A., Li, D.,
Abbruzzesse, J. L., Frazier, M. L., Killary, A. M. and Sen, S.
(2009) MicroRNAs in plasma of pancreatic ductal
adenocarcinoma patients as novel blood-based biomarkers
of disease. Cancer Prev. Res. 2, 807–813
26 Tanaka, M., Oikawa, K., Takanashi, M., Kudo, M.,
Ohyashiki, J., Ohyashiki, K. and Kuroda, M. (2009)
Down-regulation of miR-92 in human plasma is a novel
marker for acute leukemia patients. PLoS One 4, e5532
27 Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J.,
Newell, J. and Kerin, M. J. (2010) Circulating microRNAs
as novel minimally invasive biomarkers for breast cancer.
Ann. Surg. 251, 499–505
28 Sakamoto, M., Mori, T., Masugi, Y., Effendi, K., Rie, I. and
Du, W. (2008) Candidate molecular markers for
histological diagnosis of early hepatocellular carcinoma.
Intervirology 51 (Suppl. 1), 42–45
29 Tang, F., Hajkova, P., Barton, S. C., O’Carroll, D., Lee, C.,
Lao, K. and Surani, M. A. (2006) 220-plex microRNA
expression proﬁle of a single cell. Nat. Protoc. 1,
1154–1159
30 Mestdagh, P., Feys, T., Bernard, N., Guenther, S., Chen, C.,
Speleman, F. and Vandesompele, J. (2008) High-
throughput stem-loop RT-qPCR miRNA expression
proﬁling using minute amounts of input RNA. Nucleic
Acids Res. 36, e143
31 Hui, A. B., Shi, W., Boutros, P. C., Miller, N., Pintilie, M.,
Fyles, T., McCready, D., Wong, D., Gerster, K., Waldron,
L. et al. (2009) Robust global micro-RNA proﬁling with
formalin-ﬁxed parafﬁn-embedded breast cancer tissues.
Lab. Invest. 89, 597–606
32 Lu, B., Xu, J., Chen, J., Yu, J., Xu, E. and Lai, M. (2008)
TaqMan low density array is roughly right for gene
expression quantiﬁcation in colorectal cancer. Clin. Chim.
Acta 389, 146–151
33 Hu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., Chen,
Y., Xu, L., Zen, K., Zhang, C. and Shen, H. (2010) Serum
microRNA signatures identiﬁed in a genome-wide serum
microRNA expression proﬁling predict survival of
non-small-cell lung cancer. J. Clin. Oncol. 28, 1721–1726
34 Adachi, T., Nakanishi, M., Otsuka, Y., Nishimura, K.,
Hirokawa, G., Goto, Y., Nonogi, H. and Iwai, N. (2010)
Plasma microRNA 499 as a biomarker of acute myocardial
infarction. Clin. Chem. 56, 1183–1185
Received 8 June 2010/13 August 2010; accepted 3 September 2010
Published as Immediate Publication 3 September 2010, doi:10.1042/CS20100297
C   The Authors Journal compilation C   2011 Biochemical SocietyClinical Science (2011) 120, 183–193 (Printed in Great Britain) doi:10.1042/CS20100297
SUPPLEMENTARY ONLINE DATA
Serum microRNA characterization identiﬁes
miR-885-5p as a potential marker for
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Table S1 Patients’ information
Ages are given as means (S.D.), and ALT is given as the median. LC group
included seven patients with decompensated liver function.
Group
Parameter HCC LC NC
Individuals (n)2 0 1 2 1 6
Gender (n)
Male 17 11 14
Female 3 1 2
Age (years) 58.3 (6.2) 61.2 (7.5) 55.6 (4.3)
AFP
>20 ng/ml (n)9 2 0
<20 ng/ml (n)1 1 1 0 1 6
ALT (units/l) 32.7 24.5 17.4
Figure S1 Representative PCR products of U6 and miRNAs
in sera
The expected PCR products of U6 snRNA (A), miR-16 (B) and miR-885-5p and
miR-146a (C) in serum samples were generated. Single bands in each RNA
preparation demonstrate the production of corresponding PCR product. M, DL-500
DNA marker (bp).
Correspondence: Professor Yaping Tian (email tianyp61@gmail.com).
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Table S2 Raw and normalized data of miR-885-5p in independent groups of
136 serum samples including LC (n = 26), HCC (n = 46), CHB (n = 23), NC
(n = 24) and GC (n = 17)
Each sample was run in triplicate. The expression levels of miR-885-5p were normalized to U6 snRNA.
Group Number Average Ct of miR-885-5p Average Ct of U6 snRNA miR-885-5p levels
NC NC-1 32.1599 34.2276333 4.192275
NC-2 33.67397 30.7961333 0.136046
NC-3 33.57357 30.9563 0.162976
NC-4 32.86893 31.5361 0.396989
NC-5 34.91237 34.8511 0.95842
NC-6 32.46287 32.5458333 1.059191
NC-7 33.43427 31.0678667 0.193928
NC-8 32.82667 31.7420667 0.471522
NC-9 31.52813 32.8263 2.459167
NC-10 33.0165 32.5614667 0.729493
NC-11 33.17187 30.6956 0.179708
NC-12 33.76207 33.6406 0.919251
NC-13 34.23343 34.225 0.994174
NC-14 33.63983 32.5824 0.480487
NC-15 31.675 30.3933333 0.41132
NC-16 31.66773 29.0564333 0.163652
NC-17 32.1874 31.1854 0.499307
NC-18 32.5456 30.7805 0.29421
NC-19 32.12083 29.3367 0.14518
NC-20 32.91237 34.0595 2.21473
NC-21 32.39513 34.26407 3.65262
NC-22 31.98293 32.03833 1.03915
NC-23 33.84713 31.1042333 0.14938
NC-24 31.574 32.3941 1.76553
LC LC-1 33.8519 32.86523 0.504642
LC-2 29.89 32.60567 6.568816
LC-3 29.5953 33.75953 17.92871
LC-4 31.17277 31.70423 5.781591
LC-5 28.9101 32.7759 14.57914
LC-6 31.8153 32.6132 1.738569
LC-7 30.55037 32.79297 4.732492
LC-8 33.8876 35.1087 3.78703
LC-9 30.20783 34.85347 25.03081
LC-10 31.7782 32.83893 4.171983
LC-11 30.70237 33.32663 6.165708
LC-12 31.99237 34.21587 4.670251
LC-13 30.54093 34.268 13.24216
LC-14 32.1442 33.0567 1.882348
LC-15 29.56203 33.89423 20.14291
LC-16 32.284 32.3891 1.075519
LC-17 30.3293 34.2244 14.87825
LC-18 32.58497 34.81817 4.701757
LC-19 32.214 33.78757 2.976396
LC-20 33.72003 34.29103 1.485553
LC-21 29.13983 30.81847 3.201246
LC-22 28.91017 31.17233 4.797114
LC-23 29.57373 31.22837 3.148432
LC-24 29.80063 31.39323 3.015924
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Table S2 Continued
Group Number Average Ct of miR-885-5p Average Ct of U6 snRNA miR-885-5p levels
LC-25 29.71727 30.01577 1.229865
LC-26 30.77273 30.7567 0.988948
HCC HCC-1 30.84197 32.3715 2.886918
HCC-2 31.7599 32.6890667 1.904176
HCC-3 29.79517 31.2246667 2.693527
HCC-4 30.4622 33.6257 8.960008
HCC-5 29.98013 31.9065333 3.801064
HCC-6 29.64737 33.3839 13.32931
HCC-7 28.7177 31.891 9.021079
HCC-8 29.0095 32.3431667 10.0817
HCC-9 29.9224 31.8601667 3.831121
HCC-10 30.26987 31.8788333 3.050326
HCC-11 32.80137 32.4628333 0.790843
HCC-12 32.74657 32.7132333 0.977158
HCC-13 28.76793 32.7439 15.73571
HCC-14 31.87567 32.8606333 1.979263
HCC-15 29.782 33.2526 11.08549
HCC-16 29.21323 33.5275 19.89412
HCC-17 30.8785 34.1069 9.37228
HCC-18 32.4533 35.3911 7.662419
HCC-19 29.4815 31.8434667 5.140707
HCC-20 30.91573 33.4428667 5.764265
HCC-21 31.78673 33.0726 2.43829
HCC-22 31.27717 32.0824 1.747424
HCC-23 30.34453 31.7258333 2.605036
HCC-24 31.33337 31.9600333 1.54399
HCC-25 31.8361 32.4900667 1.573489
HCC-26 32.85017 34.4231333 2.975152
HCC-27 31.33333 34.106 6.833715
HCC-28 33.30637 37.1948 14.80928
HCC-29 31.67763 33.5156333 3.575149
HCC-30 32.26983 34.6443667 5.185693
HCC-31 31.14843 32.1360333 1.982888
HCC-32 32.548 33.1246333 1.491365
HCC-33 30.00793 32.5442333 5.801007
HCC-34 29.27783 31.539 4.793801
HCC-35 29.94617 31.9494333 4.009058
HCC-36 30.17673 32.3858667 4.623985
HCC-37 33.7755 32.7146333 0.479344
HCC-38 27.60693 30.4339667 7.096151
HCC-39 28.33053 32.4747 17.68152
HCC-40 31.835 29.9329667 0.267566
HCC-41 29.8067 29.3254 0.716332
HCC-42 30.01933 31.2975667 2.425424
HCC-43 30.54367 30.2766667 0.831044
HCC-44 29.90017 31.2251333 2.505265
HCC-45 29.8667 30.3007 1.350974
HCC-46 30.3879 31.3652667 1.968868
CHB CHB-1 31.5161 32.6277333 2.160901
CHB-2 32.51433 33.9452 2.696093
CHB-3 25.51897 33.7916333 309.2572
CHB-4 29.3154 31.164 3.601505
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Table S2 Continued
Group Number Average Ct of miR-885-5p Average Ct of U6 snRNA miR-885-5p levels
CHB-5 28.85253 32.7692667 15.10272
CHB-6 28.69013 30.3378667 3.133417
CHB-7 31.5974 31.2667333 0.795169
CHB-8 29.42473 32.1433 6.582201
CHB-9 28.66833 33.9994 40.25427
CHB-10 30.22393 33.8725 12.54091
CHB-11 28.49853 31.7207667 9.332326
CHB-12 29.06453 33.4399333 20.75523
CHB-13 27.39193 33.7456667 81.78343
CHB-14 28.2652 31.9182333 12.57977
CHB-15 28.2643 32.4806667 18.58886
CHB-16 32.44817 34.0811 3.101422
CHB-17 29.03807 32.8067 14.14902
CHB-18 30.19323 31.7042333 2.850082
CHB-19 28.45323 30.5798 4.36678
CHB-20 30.11127 31.8844333 3.418026
CHB-21 27.23567 32.3738 35.21529
CHB-22 30.77673 32.3135667 2.901576
CHB-23 30.91903 31.9664333 2.066806
GC GC-1 35.20143 34.4075667 0.576797
GC-2 33.84457 34.0378 1.143321
GC-3 33.2822 32.3433333 0.521642
GC-4 32.38527 32.5210667 1.098699
GC-5 35.24717 31.3213667 0.065798
GC-6 33.0854 34.9977 3.764087
GC-7 33.03173 31.3279 0.30697
GC-8 33.41497 32.997 0.748477
GC-9 33.41317 33.0260333 0.764646
GC-10 32.84237 31.0731333 0.293364
GC-11 34.34217 33.2585333 0.471838
GC-12 31.27697 31.4482333 1.126044
GC-13 32.58207 33.4471 1.821378
GC-14 33.58183 33.9913333 1.328228
GC-15 32.20793 33.2848333 2.109503
GC-16 34.1714 33.7893333 0.767338
GC-17 33.57597 32.9598 0.652401
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Table S3 The 18 potential targets of miR-885-5p predicted
by TargetScan, Microrna and miRanda respectively.
Genes Full name of predicted gene
ABCA1 ATP-binding cassette, subfamily A, member 1 (ABC1)
BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2
C12orf41 Chromosome 12 open reading frame 41
CAMK4 Calcium/calmodulin-dependent protein kinase IV
CTNNB1 Catenin (cadherin-associated protein), β1, 88kDa
EIF4G2 Eukaryotic translation initiation factor 4 γ2
FBN1 Fibrillin 1
FCHSD1 FCH and double SH3 domains 1
GRM8 Glutamate receptor, metabotropic 8
HTRA2 HtrA serine peptidase 2
KTN1 Kinectin 1 (kinesin receptor)
LIP1 Lymphocyte cytosolic protein 1 (L-plastin)
MAN1C1 Mannosidase α,c l a s s1 C ,m e m b e r1
MRPS10 Mitochondrial ribosomal protein S10
RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1
RFX1 Regulatory factor X, 1 (inﬂuences HLA class II expression)
TSC22D2 TSC22 domain family, member 2
UBE2N Ubiquitin-conjugating enzyme E2N (UBC13 homologue, yeast)
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Figure S2 Correlations between serum miR-885-5p and ALT and AFP in patients with liver pathologies
(A) The correlation of miR-885-5p and ALT in patients with liver pathologies (n = 95). (B) The changes in AFP concentrations and relative levels of serum miR-885-5p
in 46 pathologically conﬁrmed HCC patients (log10 scale of AFP concentration). The expression level of serum miR-885-5p in each patient with liver pathologies was
determined in triplicate and normalized to U6. U/L, units/l.
Figure S3 Expression of miR-885-5p in different human tissues and several cell lines
This result indicated that miR-885-5p is a relatively liver-tissue-restricted miRNA (shown with an arrow). The raw data were derived from Supplementary Table S1 in
[1]. UD, undetected; EC, endothelial cell; VSM, vascular smooth muscle; HUVEC, human umbilical vein endothelial cell; HAEC, human aortic endothelial cell.
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Figure S4 Potential targets of miR-885-5p
Bioinformatics softwares including TargetScan (http://www.targetscan.org/
vert_50/), Microrna (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/)
and miRanda (http://www.microrna.org/microrna/home.do) were used to predict
the potential targets of miR-885-5p. The result shows that 124, 985 and 1268
targets of miR-885-5p are predicted by TargetScan, Microrna and miRanda
respectively, and 18 targets are predicted by all three softwares (highlighted in
red).
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